A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease

Chronic graft-versus-host disease (cGVHD) is the most common cause of late morbidity and non-relapse mortality among patients who have undergone allogeneic hematopoietic stem cell transplantation (HCT).1 The presentation of cGVHD is highly heterogeneous and may involve multiple organ systems, often leading to detrimental impacts on quality of life and functional status.2,3 Standard first-line treatment involves prolonged systemic steroids, which can be complicated by numerous steroid-related toxicities including hyperglycemia, myopathy, and osteoporosis.

Source: Biology of Blood and Marrow Transplantation - December 24, 2022 Category: Hematology Authors: Chenyu Lin, Rachel A. DiCioccio, Tarek Haykal, William C. McManigle, Zhiguo Li, Sarah M. Anand, Jonathan C. Poe, Sonali J. Bracken, Wei Jia, Edwin P. Alyea, Adela R. Cardones, Taewoong Choi, Cristina Gasparetto, Michael R. Grunwald, Therese Hennig, Yubin Tags: AMA Source Type: research